Abstract
New designer drugs (synthetic cannabinoids and synthetic cathinones) are new “legal highs” that are sold online for recreational public or private use.
Synthetic cannabinoids are psychoactive herbal and chemical products that mimic the effects of cannabis when used. These drugs are available on the Internet or in head shops as incense or air fresheners to circumvent the law.
Cathinone is a naturally occurring beta-ketone amphetamine analog found in the leaves of the Catha edulis plant. Synthetic cathinones are phenylalkylamine derivatives that may possess amphetamine-like properties. These drugs are sold online as bath salts.
Designer drugs are often labeled as “not for human consumption” to circumvent drug abuse legislation. The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing.
There is evidence that negative health and social consequences may affect recreational and chronic users. The addictive potential of designer drugs is not negligible.
Keywords: Synthetic cannabinoids, synthetic cathinones, legal highs, recreative drugs.
Current Pharmaceutical Design
Title:New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature
Volume: 20 Issue: 25
Author(s): Olivier Cottencin, Benjamin Rolland and Laurent Karila
Affiliation:
Keywords: Synthetic cannabinoids, synthetic cathinones, legal highs, recreative drugs.
Abstract: New designer drugs (synthetic cannabinoids and synthetic cathinones) are new “legal highs” that are sold online for recreational public or private use.
Synthetic cannabinoids are psychoactive herbal and chemical products that mimic the effects of cannabis when used. These drugs are available on the Internet or in head shops as incense or air fresheners to circumvent the law.
Cathinone is a naturally occurring beta-ketone amphetamine analog found in the leaves of the Catha edulis plant. Synthetic cathinones are phenylalkylamine derivatives that may possess amphetamine-like properties. These drugs are sold online as bath salts.
Designer drugs are often labeled as “not for human consumption” to circumvent drug abuse legislation. The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing.
There is evidence that negative health and social consequences may affect recreational and chronic users. The addictive potential of designer drugs is not negligible.
Export Options
About this article
Cite this article as:
Cottencin Olivier, Rolland Benjamin and Karila Laurent, New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature, Current Pharmaceutical Design 2014; 20 (25) . https://dx.doi.org/10.2174/13816128113199990622
DOI https://dx.doi.org/10.2174/13816128113199990622 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Titration of Pharmacological Responses in ICU Patients by Quantified EEG
Current Neuropharmacology Thrombolytic Therapy in Acute Ischemic Stroke - Basic Concepts
Current Vascular Pharmacology Meet the Section Editor
Central Nervous System Agents in Medicinal Chemistry Role of Resistin in Insulin Sensitivity in Rodents and Humans
Current Protein & Peptide Science Epidemiology and Costs of Hypertension-related Disorders
Current Pharmaceutical Design Incidental Extracardiac Findings on Coronary Computed Tomography Angiography: A Pictorial Review of Imaging Findings
Current Medical Imaging Past and Present Behçet’s Disease Animal Models
Current Drug Targets Primary Tumors of the Sacrum: Imaging Findings
Current Medical Imaging Evaluation of Application Value of Transcranial Doppler (TCD) in the Inspection of Cerebral Vasospasm After the Treatment of Intracranial Aneurysm
Current Medical Imaging Strict Adherence to Guidelines in Decision Making for Coronary Angiography in Patients Who have Survived a Q Wave Myocardial Infarction; 2-Year Outcome in a Greek Population
Vascular Disease Prevention (Discontinued) Implantable Medical Devices and Tissue Engineering: An Overview of Manufacturing Processes and the Use of Polymeric Matrices for Manufacturing and Coating their Surfaces
Current Medicinal Chemistry The Urokinase Plasminogen Activator System: Role in Malignancy
Current Pharmaceutical Design Conserved Molecular Players for Axon Guidance and Angiogenesis
Current Protein & Peptide Science Noble metal-dithiocarbamates precious allies in the fight against cancer
Mini-Reviews in Medicinal Chemistry Cigarette Smoking and Hypertension
Current Pharmaceutical Design Intravitreal Bevacizumab (Avastin®) for Diabetic Retinopathy at 24-months: The 2008 Juan Verdaguer-Planas Lecture
Current Diabetes Reviews Association of Zinc and Copper Status with Cardiovascular Diseases and their Assessment Methods: A Review Study
Mini-Reviews in Medicinal Chemistry Telomere Length Variations in Aging and Age-Related Diseases
Current Aging Science Patent Selections:
Recent Patents on Cardiovascular Drug Discovery